RNA POLYMERASE VARIANTS
RNA polymerase variants enable high efficiency transcription of RNA. In Yield some embodiments, the RNA polymerase variants enable RNA transcription with high capping efficiency and/or low levels of double-stranded RNA contamination.
1 . A ribonucleic acid (RNA) polymerase variant comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 2-9, wherein the amino acid sequence comprises an amino acid substitution at position D351 and at least two additional amino acid substitutions, relative to a RNA polymerase comprising the amino acid sequence of SEQ ID NO: 1.
2 . The RNA polymerase variant of claim 1 , comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence of any one of SEQ ID NOs: 2-9.
3 . The RNA polymerase variant of claim 1 , comprising an amino acid sequence comprising the amino acid sequence of any one of SEQ ID NOs: 2-9.
4 . The RNA polymerase variant of claim 1 , comprising at least one, at least two, at least three, or at least four amino acid substitutions, relative to a wild-type T7 RNA polymerase comprising the amino acid sequence of SEQ ID NO: 1.
5 . A ribonucleic acid (RNA) polymerase variant comprising the amino acid sequence of SEQ ID NO: 6.
6 . A ribonucleic acid (RNA) polymerase variant comprising the amino acid sequence of SEQ ID NO: 7.
7 . A ribonucleic acid (RNA) polymerase variant comprising the amino acid sequence of SEQ ID NO: 8.
8 . A ribonucleic acid (RNA) polymerase variant comprising the amino acid sequence of SEQ ID NO: 9.
9 . A method comprising: producing a messenger RNA (mRNA) in an in vitro transcription reaction that comprises a DNA, nucleoside triphosphates, the RNA polymerase variant of claim 1 .
10 . The method of claim 9 , wherein the reaction further comprises a cap analog.
11 . The method of claim 10 , wherein the cap analog is a dinucleotide cap analog, a trinucleotide cap analog, or a tetranucleotide cap analog.
12 . The method of claim 11 , wherein the cap analog is a trinucleotide cap analog comprising a GAG sequence.
13 . The method of claim 11 , wherein the cap analog comprises a compound selected from:
14 . The method of claim 11 , wherein the tetranucleotide cap analog comprises a GGAG sequence.
15 . The method of claim 11 , wherein the tetranucleotide cap analog comprises a compound selected from:
16 . The method of claim 9 , wherein the DNA includes a 2′-deoxythymidine residue or a 2′-deoxycytidine residue at position +1.
17 . A composition or kit comprising the RNA polymerase variant of claim 1 and an in vitro transcription (IVT) reagent selected from the group consisting of a DNA, nucleoside triphosphates, and a cap analog.
18 . A nucleic acid encoding the RNA polymerase variant of claim 1 .